ERY974

DRUG2 trials

Sponsors

Chugai Pharmaceutical

Conditions

Hepatocellular Carcinoma (HCC)Solid Tumors

Phase 1

A Study of ERY974 in Patient With Advanced Solid Tumors

CompletedNCT02748837

Chugai PharmaceuticalSolid Tumors

Start: 2016-08-31End: 2019-08-31Updated: 2019-08-22

A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma

Active, not recruitingNCT05022927

Chugai PharmaceuticalHepatocellular Carcinoma (HCC)

Start: 2021-06-01End: 2025-12-31Target: 179Updated: 2024-09-05

Related Papers

Determination of starting dose of the T cell-redirecting bispecific antibody ERY974 targeting glypican-3 in first-in-human clinical trial

Scientific Reports2022-07-1910 citations

Abstract 5609: ERY974, a novel T cell-redirecting bispecific antibody targeting glypican-3, shows antitumor activity in gastric cancer patient-derived xenograft models with varying glypican-3 expression

Cancer Research2018-07-012 citations

A phase 1 dose escalation (DE) and cohort expansion (CE) study of ERY974, an anti-Glypican 3 (GPC3)/CD3 bispecific antibody, in patients with advanced solid tumors.

Journal of Clinical Oncology2018-05-2010 citations

Abstract 3653: Combining ERY974, a novel T cell-redirecting bispecific antibody targeting glypican-3, with chemotherapy profoundly improved antitumor efficacy over its monotherapy in xenograft model

Cancer Research2017-07-012 citations

A phase I dose escalation (DE) and cohort expansion (CE) study of ERY974, an anti-glypican 3 (GPC3)/CD3 bispecific antibody, in patients with advanced solid tumors.

Journal of Clinical Oncology2017-05-204 citations